Browse > Article

Advanced Glycation Endproduct-induced Diabetic Complications  

Lee, Hyun-Sun (Institute of Life Science and Natural Resource, Korea University)
Hong, Chung-Oui (Division of Food Bioscience and Technology, College of Life Science and Biotechnology, Korea University)
Lee, Kwang-Won (Division of Food Bioscience and Technology, College of Life Science and Biotechnology, Korea University)
Publication Information
Food Science and Biotechnology / v.17, no.6, 2008 , pp. 1131-1138 More about this Journal
Abstract
Diabetic complications are a leading cause of blindness, renal failure, and nerve damage. Additionally, diabetes-accelerated atherosclerosis leads to increased risk of myocardial infarction, stroke, and limb amputation. At the present time, 4 main molecular mechanisms have been implicated in hyperglyceamia-mediated vascular damage. In particular, advanced glycation endproducts (AGE), which are formed by complex, heterogeneous, sugar-derived protein modifications, have been implicated as a major pathogenic process for diabetic complications. Recently, AGE inhibitors such as aminoguanidin, ALT-946, and pyridoxamine have been reported. Such an integrating paradigm provides a new conceptual framework for future research on diabetes complications and on discovering drugs to prevent the progression of AGE-induced maladies.
Keywords
advanced glycation endproduct; diabetes mellitus; diabetic complication; inhibitor; reactive oxygen species (ROS);
Citations & Related Records

Times Cited By Web Of Science : 1  (Related Records In Web of Science)
Times Cited By SCOPUS : 1
연도 인용수 순위
1 Argoff CE, Cole BE, Fishbain DA, Irving GA. Diabetic peripheral neuropathic pain: Clinical and quality-of-life issues. Mayo Clin. Proc. 81: 3-11 (2006)   DOI   ScienceOn
2 Vlassara H, Stricker LJ, Teichberg S, Fuh H, Li YM, Steffes M. Advanced glycation end-products induce glomerular sclerosis and albuminuria in normal rats. P. Natl. Acad. Sci. USA 91: 11704-11708 (1994)
3 Pacher P, Szabo C. Role of poly (ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: Endothelial dysfunction, as a common underlying theme. Antioxid. Redox. Sign. 7: 1568-1580 (2004)   DOI   ScienceOn
4 Ii S, Ohta M, Kudo E, Yamaoka T, Tachikawa T. Redox statedependent and sorbitol accumulation-independent diabetic albuminuria in mice with transgene-derived human aldose reductase and sorbitol dehydrogenase deficiency. Diabetologia 47: 541-544 (2004)   DOI   ScienceOn
5 Takeuchi M, Kikuchi S, Sasaki N, Suzuki T, Watai T, Iwaki Bucala R, Yamagishi S. Involvement of advanced glycation end-products (AGEs) in Alzheimer's disease. Curr. Alzheimer Res. 1: 39-46 (2004)   DOI   ScienceOn
6 Lusis AJ. Atherosclerosis. Nature 407: 233-241 (2000)   DOI   ScienceOn
7 Nawroth PP, Bierhaus A, Vogel GE, Hofmann MA, Zumbach M, Wahl P, Ziegler R. Non-enzymaticglycation and oxidative stress in chronic illness and diabetes mellitus. Med. Klin. 94: 29-38 (1999)
8 Rumble JR, Cooper ME, Soulis-Liparota T, Cox A, Wu L. Vascular hypertrophy in experimental diabetes: Role of advanced glycation end-products. J. Clin. Invest. 99: 1016-1027 (1997)   DOI   ScienceOn
9 Yan SD, Schmidt AM, Anderson MG, Zhang J, Brett J. Enhanced cellular oxidant stress by the interaction of advanced glycation endproducts with their receptors/binding proteins. J. Biol. Chem. 269: 9889-9897 (1994)
10 Galle J, Lenhmann-Bodem C, Hubner U, Heinloth A, Wanner C. CyA and OxLDL cause endothelial dysfunction in isolated arteries through endothelinmediated stimulation of O(2)(-) formation. Nephrol. Dial. Transpl. 15: 339-346 (2000)   DOI   ScienceOn
11 Schleicher E, Friess U. Oxidative stress, AGE, and atherosclerosis. Kidney Int. Suppl. 106: 17-26 (2007)
12 Matsuzawa-Nagata N, Takamura T, Ando H, Nakamura S, Kurita S, Misu H, Ota T, Yokoyama M, Honda M, Miyamoto K, Kaneko S. Increased oxidative stress precedes the onset of high-fat dietinduced insulin resistance and obesity. Metabolism 57: 1071-1077 (2008)   DOI   ScienceOn
13 Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57: 1446-1454 (2008)   DOI   ScienceOn
14 Ha H, Lee HB. Reactive oxygen species amplify glucose signalling in renal cells cultured under high glucose and in diabetic kidney. Nephrology 10: 7-10 (2005)   DOI   ScienceOn
15 Munzel T, Heitzer T, Harrison DG. The physiology and pathophysiology of the nitric oxide/superoxide anions. Herz 22: 158-172 (1997)   DOI   ScienceOn
16 Flyvberg A, Denner L, Schrijvers B, Tilton RG, Mogensen TH, Paludan SR. Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes 53: 166-172 (2004)   DOI
17 Jensen IJ, Denner I, Schrijers BF, Tilton RG, Rash R, Flyvgerg A. Renal effects of a neutralizing RAGE-antibody in long-term streptozotocin-diabetic mice. J. Endocrinol. 188: 493-501 (2006)   DOI   ScienceOn
18 Booth AA, Khalifah RG, Todd P, Hudson BG. In vitro kinetics studies of formation of antigenic advanced glycation end products (AGEs). J. Biol. Chem. 272: 5387-5430 (1997)
19 Voziyan PA, Hudson BG. Pyridoxamine: The many virtues of a maillard reaction inhibitor. Ann. NY Acad. Sci. 1043: 807-816 (2005)   DOI   ScienceOn
20 Vasan S, Foiles P, Founds H. Therapeutic potential odd breakers of advanced glycation end product-protein cross links. Arch. Biochem. Biophys. 419: 89-96 (2003)   DOI   ScienceOn
21 Voziyan PA, Metz TO, Baynes JW, HudsonBG. A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J. Biol. Chem. 277: 3397-3403 (2002)   DOI   ScienceOn
22 Vasan S, Zhang X, Karpurniotu A, Bernhagen J, Teichberg S. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 382: 211-212 (1996)   DOI
23 Evans E, Patry R. Management of gestational diabetes mellitus and pharmacists' role in patient education. Am. J. Health-Syst. Ph. 61: 1460-1465 (2004)
24 Williamson JR, Chang K, Frangos M, HasanKS, Ido Y, Kawamura T, Nyengaard JR, Enden M, Kilo C, Tilton RG. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42: 801-813 (1993)   DOI   ScienceOn
25 Galle J, Schneider R, Winner B, Lehmann-Boden C, Schinzel R. Glyco-oxidized LDL impair endothelial function more potently than oxidized LDL: Role of enhanced oxidative stress. Atherosclerosis 138: 65-77 (1998)   DOI   ScienceOn
26 Hammes HP, Du X, Edelstein D, Taguchi T, Matsumara T, Ju Q. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat. Med. 9: 294-299 (2003)   DOI   ScienceOn
27 Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D. Cellular receptors for advanced glycation end-products: Implication for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler. Thromb. 14: 1521-1527 (1994)   DOI
28 Goova MT, Li J, Kislinger T, Qu W, Lu Y, Bucciarelli LG. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am. J. Pathol. 159: 513-525 (2001)   DOI   ScienceOn
29 Price DL, Rhett PM, Thorpe SR, Baynes JW, Chelating activity of advanced glycation end-product inhibitors. J. Biol. Chem. 276: 48967-48972 (2001)   DOI   ScienceOn
30 Donato R. RAGE: A single receptor for several ligands and different cellular responses: The case of certain S100 proteins. Curr. Mol. Med. 7: 711-724 (2007)   DOI   ScienceOn
31 Palm F. Intrarenal oxygen in diabetes and a possible link to diabetic nephropathy. Clin. Exp. Pharmacol. P. 33: 997-1001 (2006)   DOI   ScienceOn
32 Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820 (2001)   DOI   ScienceOn
33 Goldin A, Joshua AB, Schmidt AM, Creager MA. Advanced glycation end products sparking the development of diabetic vascular injury. Circulation 114: 597-605 (2006)   DOI   ScienceOn
34 Pieper GM, Dondlinger LA. Plasma and vascular tissue arginine are decreased in diabetes: Acute arginine supplementation restores endotheliumdependent relaxation by augmenting cGMP. J. Pharmacol. Exp. Ther. 283: 684-691 (1997)
35 Thornalley PJ, Yurek-George A, Argirov AK. Kinetics and mechanism of the reaction of aminoguanidine with alphaoxaldehydes glyoxal, methylglyoxal, and 3-deoxyglucosone under physiological conditions. Biochem. Pharmacol. 60: 55-65 (2000)   DOI   ScienceOn
36 Chen XM, Kitts DD. Determining conditions for nitric oxide synthesis in Caco-2 cells using Taguchi and factorial experimental designs. Anal. Biochem. 381: 185-192 (2008)   DOI   ScienceOn
37 Bakris GL, Bank AJ, Kass DA, Neutel JM, Preston RA, Oparil S. Advanced glycation end-product cross-link breakers: A novel approach to cardiovascular pathologies related to the aging process. Am. J. Hypertens.17: 23-30 (2004)
38 Somoza V. Five years of research on health risks and benefits of Maillard reaction products: An update. Mol. Nutr. Food Res. 49: 663-672 (2005)   DOI   ScienceOn
39 Abebe W, MacLeod KM. Protein kinase C-mediated contractile responses of arteries from diabetic rats. Brit. J. Pharmacol. 101: 465-471 (1990)   DOI   ScienceOn
40 Takeuchi M, Makita Z, Yanagisawa K, Kameda Y, Koike T. Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients. Mol. Med. 5: 393-405 (1999)
41 Babei-jadidi R, Karachalian N, Ahmed N, Battab S, Thornalley PJ. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 52: 2110-2120 (2003)   DOI   ScienceOn
42 Sato T, Shimogaito N, Wu X, Kikuchi S, Yamagishi S, Takeuchi M. Toxic advanced glycation end products (TAGE) theory in Alzheimer's disease. Am. J. Alzheimers Dis. Other Demen. 21: 197-208 (2006)   DOI   ScienceOn
43 Kakkar R, Mantha SV, Kalra J, Prasad K. Time course study of oxidative stress in aorta and heart of diabetic rats. Clin. Sci. 91: 441-448 (1996)   DOI
44 Onorato JM, Jenkins AJ, Thorpe SR, Baynes JW. Pyrodoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. J. Biol. Chem. 275: 21177-21184 (2000)   DOI   ScienceOn
45 Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW. Ne-(carboxymethyl) lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 34: 10872-10878 (1995)   DOI   ScienceOn
46 Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB for the ACTIONI Investigator Group. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am. J. Nephrol. 24: 32-40 (2004)   DOI   ScienceOn
47 Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. AGEs and their interactions with AGE receptors in vascular disease and diabetes mellitus: AGE concept. Cardiovasc. Res. 37: 586-600 (1998)   DOI   ScienceOn
48 Hein G, Wiegand R, Lehmann G, Stein G, Franke S. Advanced glycation end-products pentosidine and N-carboxymethyllysine are elevated in serum of patients with osteoporosis. Rheumatology 42: 1242-1246 (2003)   DOI   ScienceOn
49 Peyroux J, Sternberg M. Advanced glycation endproducts (AGEs): Pharmacological inhibition in diabetes. Pathol. Biol. 54: 405-419 (2006)   DOI   ScienceOn
50 Little WC, Zile MR, Kitzman DW, Hundley WG, O'Brien TX, Degroof RC. The effect of alagebrium chloride (ALT 711), a novel glucose crosslink breaker, in treatment of elderly patients with diastolic heart failure. J. Card. Fail. 11: 191-195 (2005)   DOI   ScienceOn
51 Yamagishi S, Nakamura K, Matsui T. Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy. Curr. Drug. Discov. Technol. 3: 83-88 (2006)   DOI   ScienceOn
52 Jang DS, Kim JM, Lee YM, Kim YS, Kim JH, Kim JS. Puerariafuran, a new inhibitor of advanced glycation end products (AGEs) isolated from the roots of Pueraria lobata. Chem. Pharm. Bull. 54: 1315-1317 (2006)   DOI   ScienceOn
53 Misawa S, Kuwabara S, Kanai K, Tamura N, Nakata M, Sawai S, Yagui K, Hattori T. Aldose reductase inhibition alters nodal $Na^+$ currents and nerve conduction in human diabetics. Neurology 66: 1545-1549 (2006)   DOI   ScienceOn
54 Miyata T, Yamamoto M, Izuhara Y. From molecular footprints of disease to new therapeutic interventions in diabetic nephropathy. Ann. NY Acad. Sci. 1043: 740-749 (2005)   DOI   ScienceOn
55 Legan E. Effects of streptozotocin-induced hyperglycemia on agonist-stimulated phosphoinositol turnover in rat aorta. Life Sci. 45: 371-378 (1989)   DOI   ScienceOn
56 Hill MA, Ege EA. Active and passive mechanical properties of isolated arterioles from STZ-induced diabetic rats: Effect of aminoguanidine treatment. Diabetes 43: 1450-1456 (1994)   DOI   ScienceOn
57 Wang YK, Hong YJ, Huang ZQ. Protective effects of silybin on human umbilical vein endothelial cell injury induced by $H_2O_2$ in vitro. Vasc. Pharmacol. 43: 198-206 (2005)   DOI   ScienceOn
58 Weissman AJ. Intensive diabetes treatment and cardiovascular disease. New Engl. J. Med. 354: 1751-1752 (2006)   DOI
59 Chappey O, Dosquet C, Wautier MP, Wautier JL. Advanced glycation end-products, oxidant stress, and vascular lesions. Eur. J. Clin. Invest. 27: 97-108 (1997)   DOI   ScienceOn
60 Thornalley PJ. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch. Biochem. Biophys. 419: 31-40 (2003)   DOI   ScienceOn
61 Suzuki D, Miyata T, Saotome N, Horie K, Inagi R. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesion. J. Am. Soc. Nephrol. 10: 822-832 (1999)
62 Service FJ, Rizza RA, Daube JR, O'Brian PC, Dyck PJ. Near normoglycaemia improved nerve conduction and vibration in diabetic neuropathy. Diabetologia 28: 722-727 (1985)
63 Voziyan PA, Khalifah RG, Thibaudeau C, Yildiz A, Jacob J, Seriani S. Modification of proteins in vitro by physiological levels of glucose. J. Biol. Chem. 278: 46616-46624 (2003)   DOI   ScienceOn
64 Yang S, Litchfield JE, Baynes JW. AGE-breakers cleave model compounds but not break Maillard crosslinks in skin and tail collagen from diabetic rats. Arch. Biochem. Biophys. 412: 42-46 (2003)   DOI   ScienceOn
65 Sarti C, Gallagher J. The metabolic syndrome: Prevalence, CHD risk, and treatment. J. Diabetes Complicat. 20: 121-132 (2006)   DOI   ScienceOn
66 Xu Y, He Z, King GL. Introduction of hyperglycemia and dyslipidemia in the pathogenesis of diabetic vascular complications. Curr. Diab. Rep. 5: 91-97 (2005)   DOI   ScienceOn
67 Zeng J, Dunlop RA, Rodgers KJ, Davies MJ. Evidence for inactivation of cysteine proteases by reactive carbonyls via glycation of active site thiols. Biochem. J. 398: 197-206 (2006)   DOI   ScienceOn
68 Odetti P, Aragno I, Rolandi R, Garibaldi S, Valentini S. Scanning force microscopy reveals structural alterations in diabetic rat collagen fibrils: Role of protein glycation. Diabetes Metab. 16: 74-81 (2000)   DOI   ScienceOn
69 Wirasathien L, Pengsuparp T, Suttisri R, Ueda H, Moriyasu M, Kawanishi K. Inhibitors of aldose reductase and advanced glycation end-products formation from the leaves of Stelechocarpus cauliflorus R.E. Fr. Phytomedicine 14: 546-550 (2007)   DOI   ScienceOn
70 Kolm-Litty V, Sauer U, Nerlich A, Lehmann R, Schleicher ED. High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. J. Clin. Invest. 101: 160-169 (1998)   DOI   ScienceOn
71 Miyata T, Ueda Y, Yamada Y, Izuhara Y, Wada T, Jadoui M. Accumulation of carbonyls accelerates the formation of pentosidine, advanced glycation end product: Carbonyl stress in uremia. J. Am. Soc. Nephrol. 9: 2349-2356 (1998)
72 Figarola JL, Scott S, Loera S, Xi B, Synold T, Weiss I. Prevention of early renal disease, dyslipidemia, and lipid peroxidation in STZ-diabetic rats by LR-9 and LR-74 novel AGE inhibitors. Diabetes Metab. Res. 21: 533-544 (2005)   DOI   ScienceOn
73 Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. New Engl. J. Med. 329: 304-309 (1993)   DOI   ScienceOn